The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review
Article 2022 en
Authors
KT
Kalthoum Tizaoui
JY
Jae Won Yang
KL
Keum Hwa Lee
Abstract
1 min read
YKL-40, a chitinase-3-like protein 1 (CHI3L1) or human cartilage glycoprotein 39 (HC gp-39), is expressed and secreted by various cell-types including macrophages, chondrocytes, fibroblast-like synovial cells and vascular smooth muscle cells. Its biological function is not well elucidated, but it is speculated to have some connection with inflammatory reactions and autoimmune diseases. Although having important biological roles in autoimmunity, there were only attempts to elucidate relationships of YKL-40 with a single or couple of diseases in the literature. Therefore, in order to analyze the relationship between YKL-40 and the overall diseases, we reviewed 51 articles that discussed the association of YKL-40 with rheumatoid arthritis, psoriasis, systemic lupus erythematosus, Behçet disease and inflammatory bowel disease. Several studies showed that YKL-40 could be assumed as a marker for disease diagnosis, prognosis, disease activity and severity. It is also shown to be involved in response to disease treatment. However, other studies showed controversial results particularly in the case of Behçet disease activity. Therefore, further studies are needed to elucidate the exact role of YKL-40 in autoimmunity and to investigate its potential in therapeutics.
Thomas Berg, Ralf Weiskirchen, Christian Trautwein, Hermann E. Wasmuth, Marie‐Luise Berres, Sven Papen, K Pauels, P Schmitz, Mirko Moreno Zaldivar, Claus Hellerbrand, Tobias Mueller
Hyo Jin An, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Keum Hwa Lee, Seoung Wan Nam, Jae‐Seok Kim, Jae Won Yang, Jun Young Lee, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Jae Il Shin, Andreas Kronbichler
Min Ho Lee, Jae Il Shin, Jae Won Yang, Keum Hwa Lee, Do Hyeon Cha, Jun Beom Hong, Yeoeun Park, Eugene Choi, Kalthoum Tizaoui, Ai Koyanagi, Louis Jacob, Seoyeon Park, Ji Hong Kim, Lee Smith
Discussion(0)
No comments yet. Be the first to comment.